MedinCell SA (FR:MEDCL)
:MEDCL
MEDCL Stock Chart & Stats
€23.10
-€0.24(-1.39%)
At close: 4:00 PM EST
€23.10
-€0.24(-1.39%)
Day’s Range― - ―
52-Week Range€12.00 - €39.68
Previous CloseN/A
Volume18.50K
Average Volume (3M)179.66K
Market Cap
€829.37M
Enterprise Value€868.20M
Total Cash (Recent Filing)€53.50M
Total Debt (Recent Filing)€58.27M
Price to Earnings (P/E)―
Beta0.98
Next Earnings
Jun 16, 2026EPS Estimate
0.02Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.49
Shares Outstanding35,907,510
10 Day Avg. Volume204,359
30 Day Avg. Volume179,664
Financial Highlights & Ratios
PEG Ratio0.80
Price to Book (P/B)-25.60
Price to Sales (P/S)16.41
P/FCF Ratio23.54
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€36.60Price Target Upside58.44% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)0.27
Revenue Forecast (FY)€51.54M
Bulls Say, Bears Say
Bulls Say
Strong Revenue GrowthSustained top-line expansion near 100% indicates strong commercial traction and partnership-driven royalties (UZEDY). Durable revenue growth improves runway and validates the BEPO® platform's market fit, supporting continued investment in pipeline and de-risking long-term cash generation.
Proprietary LAI Platform And PartnershipsOwning a differentiated sustained‑release platform plus collaborations with major pharma (Teva, AbbVie) creates scalable licensing and milestone streams. These structural partnerships leverage partners' commercial scale and reduce MedinCell's go‑to‑market risk while expanding future royalty potential across therapeutic areas.
Cash Runway And Operating Cash GenerationA multi‑year cash visibility and positive operating cash flow lower short‑term financing pressure and allow continued R&D and milestone investments. This supports pipeline progression and partnership de-risking over the next 2–6 months without immediate dilutive capital raises.
Bears Say
High Leverage And Negative EquityLiabilities exceeding assets and significant leverage are structural red flags that constrain strategic flexibility. Negative equity distorts metrics (ROE) and increases refinancing and covenant risk, making long‑term funding and M&A optionality more expensive or uncertain.
Persistent Unprofitability And Weak MarginsDeep negative margins reflect fundamental operating losses requiring ongoing funding from partners or capital markets. Without sustainable margin improvement, reliance on milestones and royalties may not cover op costs long term, limiting ability to scale independently or absorb setbacks in partner programs.
Rising Operating Expenses And FCF PressureMaterial OpEx growth from R&D expansion raises the burn rate and puts pressure on free cash flow. Even if R&D is partner‑backed, rising costs increase the need for milestone receipts or capital, heightening dilution or refinancing risk if clinical progress or partner payments are delayed.
MedinCell SA News
MEDCL FAQ
What was MedinCell SA’s price range in the past 12 months?
MedinCell SA lowest stock price was €12.00 and its highest was €39.68 in the past 12 months.
What is MedinCell SA’s market cap?
MedinCell SA’s market cap is €829.37M.
When is MedinCell SA’s upcoming earnings report date?
MedinCell SA’s upcoming earnings report date is Jun 16, 2026 which is in 72 days.
How were MedinCell SA’s earnings last quarter?
MedinCell SA released its earnings results on Dec 09, 2025. The company reported -€0.49 earnings per share for the quarter, missing the consensus estimate of -€0.18 by -€0.31.
Is MedinCell SA overvalued?
According to Wall Street analysts MedinCell SA’s price is currently Undervalued.
Does MedinCell SA pay dividends?
MedinCell SA does not currently pay dividends.
What is MedinCell SA’s EPS estimate?
MedinCell SA’s EPS estimate is 0.02.
How many shares outstanding does MedinCell SA have?
MedinCell SA has 35,907,510 shares outstanding.
What happened to MedinCell SA’s price movement after its last earnings report?
MedinCell SA reported an EPS of -€0.49 in its last earnings report, missing expectations of -€0.18. Following the earnings report the stock price went down -0.75%.
Which hedge fund is a major shareholder of MedinCell SA?
Currently, no hedge funds are holding shares in FR:MEDCL
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
MedinCell SA
MedinCell S.A. develops various therapeutic solutions. It develops solutions based on BEPO, a technology for long-acting injectable products based on proprietary copolymers and a biocompatible solvent, which solubilizes or suspends the active pharmaceutical ingredients. The company's products in development include mdc-IRM, a subcutaneous injection in Phase III trials for use in the treatment of schizophrenia; mdc-CWM, an intra-articular injection to treat pain and inflammation; and mdc-TJK, a subcutaneous injection in preclinical trials for use in the treatment of schizophrenia. Its product candidates in formulation research comprise subcutaneous injections, such as mdc-WWM for contraception; mdc-ANG for CNS related treatments; mdc-ELK for depression; and mdc-GRT for use in organ transplant, as well as perineural injections, including mdc-CMV for anesthesia and pain, and mdc-NVA for pain. The company is based in Jacou, France.
MEDCL Stock 12 Month Forecast
Average Price Target
€36.60
▲(58.44% Upside)
Technical Analysis
Options Prices
Currently, No data available
---